Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
– Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization – – Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 – – Completed Drug-Drug Interaction (“DDI”) study […]
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
